Back to top

oncology-screening: Archive

Zacks Equity Research

NuCana Stock Soars 151% on Upbeat Efficacy Data From Melanoma Study

NCNA stock surges 151% on positive efficacy data from the mid-stage melanoma study of NUC-7738 in combination with Merck's Keytruda.

BMYNegative Net Change MRKNegative Net Change ILMNPositive Net Change NCNANegative Net Change

Zacks Equity Research

Zentalis Stock Up as FDA Lifts Partial Hold on Cancer Drug Studies

ZNTL stock gains as the FDA lifts clinical hold on studies of its lead candidate, azenosertib, which is being developed for different cancer indications.

GSKNegative Net Change ILMNPositive Net Change FULCPositive Net Change ZNTLPositive Net Change

Zacks Equity Research

IMRX Stock Soars on Upbeat Efficacy Data From Pancreatic Cancer Study

Immuneering stock soars 41% as lead drug combo regimen shows superior initial efficacy in the first-line treatment of pancreatic cancer in a mid-stage study.

ILMNPositive Net Change KRYSPositive Net Change FULCPositive Net Change IMRXPositive Net Change

Zacks Equity Research

Aura Stock Up as Lead Drug Shows Superior Efficacy in Eye Cancer Study

AURA stock up as lead candidate shows tumor control and visual acuity preservation abilities in eye cancer patients over 12 months of treatment.

ILMNPositive Net Change KRYSPositive Net Change FULCPositive Net Change AURAPositive Net Change

Ahan Chakraborty

Boost Your Portfolio's Health With These 4 Large-Cap Drug Stocks

Here are four big drug/biotech stocks, LLY, RHHBY, NVS and PFE, which you should buy today for lucrative long-term returns.

NVSPositive Net Change RHHBYNegative Net Change PFENegative Net Change LLYPositive Net Change

Moumi Mondal

With HOLX Stock Near 52-Week High, Should You Buy More or Play Safe?

Hologic's business diversification holds strong potential internationally. Also, its discounted valuation makes it attractive from an investment perspective.

BDXPositive Net Change HOLXPositive Net Change QGENNegative Net Change